Providence, RINCT06319027Now EnrollingIRB Ready

Glioblastoma, IDH-Wildtype Clinical Trial in Providence, RI

Access cutting-edge glioblastoma, idh-wildtype treatment through this clinical trial at a research site in Providence. Study-provided care at no cost to qualified participants.

Sponsored by ECOG-ACRIN Cancer Research Group

Quick Self-Assessment

See if you qualify for this Providence location

Preparing your pre-screening questions…

Expert Care in Providence

Access glioblastoma, idh-wildtype specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related glioblastoma, idh-wildtype treatment provided free

Apply for This Providence Location

Check if you qualify for this glioblastoma, idh-wildtype clinical trial in Providence, RI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Providence

    Convenient for RI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Providence site if eligible
  4. 4Begin participation

About This Glioblastoma, IDH-Wildtype Study in Providence

This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI). This study is trying to learn more about the meaning of changes in MRI scans after treatment, as while the appearance of some of these changes may reflect progressing tumor, some may be due the treatment. Dynamic susceptibility contrast (DSC)-MRIs, along with positron emission tomography (PET) and/or magnetic resonance (MR) spectroscopy, may help doctors tell which changes are a reflection of the treatment and which changes may be due to progressing tumor.

Sponsor: ECOG-ACRIN Cancer Research Group

Who Can Participate

Inclusion Criteria

Patient must be ≥ 18 years of age.
Patient must have a Karnofsky Performance Status ≥ 60%.
Patient must have newly diagnosed GBM (must be IDH wild type), with pathologic proof, based on World Health Organization (WHO) 2021 criteria.
Patient must be planning to receive standard-of-care treatment for newly diagnosed glioblastoma.
Patient must have completed an MRI prior to the diagnostic surgery for GBM and have images available for upload into Transfer of Images and Data (TRIAD).
Patient must have diagnostic surgery for GBM within 7 weeks prior to registration.
Patient must have O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status ordered at time of registration.
Patient must have a post-operative (op) MRI completed within 3 weeks after diagnostic surgery for GBM and have images available for upload into TRIAD.
Patient must have no contraindications to MRI, including injection of gadolinium-based contrast agents, and demonstrated ability to tolerate MRI on pre-surgical imaging.
Patient must have no allergies to agents that may potentially be used for non-standard of care imaging (18F-fluciclovine, MR contrast).
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the interventions being used.
All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy.
A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible.
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Providence?

Yes, this clinical trial (NCT06319027) has an active research site in Providence, RI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Glioblastoma, IDH-Wildtype Treatment Options in Providence, RI

If you're searching for glioblastoma, idh-wildtype treatment options in Providence, RI, this clinical trial (NCT06319027) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Providence research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma, idh-wildtype specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all glioblastoma, idh-wildtype clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Providence, RI

See all brain cancer clinical trials recruiting in Providence — not just this study.

Browse Brain Cancer Trials in Providence →

Browse More Trials by Condition

Brain Cancer TrialsPulmonary Embolism TrialsAnkylosing Spondylitis TrialsInterstitial Lung Disease TrialsAll Conditions →

Ready to Join in Providence?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Providence, RI